Explore
This book explores the crucial role that Human Epidermal Growth Factor Receptor 2 (HER2) plays in the initiation and progression of cancer, as well as cutting-edge molecular mechanisms, precision medicine, and novel targeted treatments, including lapatinib, pertuzumab, and trastuzumab. HER2 overexpression, especially for breast cancer and beyond, in combination with other development therapies, antibody-drug conjugates, and overcomes resistance mechanisms. This book provides comprehensive coverage of the PI3K/AKT and MAPK signaling pathways, up-to-date information on next-generation HER2 inhibitors, including neratinib and tucatinib, and offers helpful advice for researchers and clinicians managing HER2-positive tumors. This book, which links laboratory findings with clinical applications and offers hope for better outcomes in HER2-driven cancers, is an essential resource for oncologists, molecular biologists, and pharmaceutical scientists. It does so clearly and understandably.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 1 times via unglue.it ebook links.
- 1 - pdf (CC BY) at intech-files.s3.amazonaws.com.
Keywords
- Medical / Prosthesis
- thema EDItEUR::M Medicine and Nursing::MQ Nursing and ancillary services::MQW Biomedical engineering::MQWP Prosthetics
Links
DOI: 10.5772/intechopen.1006255Editions